Anthony Bazarko joins Specific Diagnostics as Chief Commercial Officer

Share Article

Specific Diagnostics today announced the appointment of Anthony Bazarko as Chief Commercial Officer, as it begins its market launch in Europe. Mr. Bazarko is an industry veteran with over 15 years of senior leadership experience, having most recently served as the Vice President of Commercial Development, Americas and General Manager of Canada at Dana-her Corporation’s subsidiary Leica Biosystems.

"I am honored to have the opportunity to lead Specific Diagnostic's commercial operation globally and ensure this critically important diagnostic capability is available to patients around the world.”

Specific Diagnostics today announced the appointment of Anthony Bazarko as Chief Commercial Officer, as it begins its market launch in Europe. Mr. Bazarko is an industry veteran with over 15 years of senior leadership experience, having most recently served as the Vice President of Commercial Development, Americas and General Manager of Canada at Dana-her Corporation’s subsidiary Leica Biosystems ($1B in 2019 sales). Prior to Dana-her, Mr. Bazarko was the Senior Director of Strategic Affairs – Americas at Roche Diagnostics Corporation. Mr. Bazarko will oversee the implementation of Specific’s global commercial operations overseeing its market launch in Europe and subsequent launch in the US.

“Tony is coming in at a pivotal moment and is going to be a great asset to our team at Specific,” said Dr. Paul A. Rhodes, Specific’s CEO. “With the recent hire of Alain Richard as our Head of Commercial Operations, EMEA and now Tony Bazarko as our CCO we have put a superb Danaher-bred team together that is going to be greatly beneficial to our commercialization in Europe and the US as we release our Reveal rapid susceptibility testing instrument and associated disposables.”

“The Specific Diagnostics’ team has developed a platform that will have a profound impact on patient outcomes,” said Mr. Bazarko. “The vision and mission of this company is going to enable hospitals and healthcare systems around the world to take one further step in the quest for truly personalized medicine. I am honored to have the opportunity to lead Specific Diagnostic's commercial operation globally and ensure this critically important diagnostic capability is available to patients around the world.”

During his time within Danaher, Mr. Bazarko developed and executed go-to-market strategies that maximized sales and share gain potential - he achieved double digit growth on a $500M business in North America and led Canada to 18% growth in 2019. While serving as the Senior Director of strategic Affairs at Roche Diagnostics his team lead the restructuring of the North American Commercial team across five verticals and helped implement strategic direction across multiple business units that totaled $2.4B.

About Specific

Specific Diagnostics has developed in vitro diagnostic systems based upon a unique, patented metabolomic signature technology that enables rapid detection and identification of microorganisms as they growth in culture. Its first commercial application applies this fundamental new platform to the rapid determination of antimicrobial susceptibility directly from positive blood cultures, as well as isolate dilutions. Specific is based in Mountain View, CA.

For press inquiries, please contact: press@specificdx.com

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Visit website